WEDNESDAY, May 14, 2025 -- Migraines don’t just cause headaches. These attacks often are accompanied by symptoms like light and sound sensitivity, nausea, neck pain and dizziness. What’s more, those non-headache symptoms tend to crop. MORE
Covalent Modifiers
JULY 24, 2025
Yoav Shamir, Nir London bioRxiv 2025.03.19.642201 doi: [link] Recent years have seen an explosion in the prominence of covalent inhibitors as research and therapeutic tools. However, a lag in application of computational methods for covalent docking slows progress in this field. AI models such as AlphaFold3 have shown accuracy in ligand pose prediction but were never assessed for virtual screening.
Science Daily: Pharmacology News
JULY 25, 2025
A virus from humble black-eyed peas is showing extraordinary promise in the fight against cancer. Unlike other plant viruses, the cowpea mosaic virus (CPMV) can awaken the human immune system and transform it into a cancer-fighting powerhouse, without infecting human cells. By comparing it to a similar, but ineffective, virus, researchers uncovered that CPMV uniquely triggers potent interferons and immune responses, making it a low-cost, plant-grown immunotherapy on the fast track toward clinica
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Science Daily: Pharmacology News
JULY 18, 2025
A gene called SDR42E1 has been identified as a key player in how our bodies absorb and process vitamin D. Researchers found that disabling this gene in colorectal cancer cells not only crippled their survival but also disrupted thousands of other genes tied to cancer and metabolism. This opens the door to highly targeted cancer therapies—by either cutting off vitamin D supply to tumors or enhancing the gene’s activity to boost health.
Broad Institute
JULY 21, 2025
Prime editing treats childhood brain disease in mice By Corie Lok July 21, 2025 Breadcrumb Home Prime editing treats childhood brain disease in mice Scientists use a precise form of gene editing called prime editing to correct the most common genetic mutations that cause alternating hemiplegia of childhood, a rare and severe neurological disorder that begins in infancy.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drug Target Review
JULY 21, 2025
Hundreds of life-altering conditions attack the central nervous system (CNS). Disorders such as Alzheimer’s disease , primary glioblastoma and amyotrophic lateral sclerosis (ALS) all affect the CNS and are considered fatal, while more common conditions, including depression , strokes and epilepsy , require long-term treatments. According to the World Health Organization (WHO) , neurological conditions are now the number one cause of ill health and disability across the globe, 1 highlighting the
Perficient: Drug Development
JULY 18, 2025
You can think of the Model Context Protocol (MCP) as USB for large language models (LLMs), allowing an LLM to interact with a variety of external systems in a uniform manner. It was developed by Anthropic to solve the fundamental problem of getting a text generator (LLM) to perform real-world actions on a user’s behalf. Solving the M x N Problem With a growing number of powerful LLMs (M) and a vast universe of applications and APIs (N) for them to interact with, one would need to develop M
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Science Daily: Pharmacology News
JULY 20, 2025
Using a clever combo of iron and radical chemistry, scientists have unlocked a safer, faster way to create carbenes molecular powerhouses key to modern medicine and materials. It s 100x more efficient than previous methods.
Broad Institute
JULY 24, 2025
Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets By Leah Eisenstadt July 24, 2025 Breadcrumb Home Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets Combining powerful imaging, perturbational screening, and machine learning, researchers uncover new human host factors that alter Ebola’s ability to infect.
Drug Target Review
JULY 24, 2025
Antibody therapies have transformed cancer treatment, yet their limits are becoming increasingly clear – particularly when tumours evolve, evade immune detection or develop resistance to existing drugs. For Dr Jhong-Jhe ‘JJ’ You, Vice President of Antibody Discovery at AP Biosciences, these challenges are not setbacks. They are starting points. With a background in neurobiology, immuno-oncology and bispecific engineering, JJ now leads the development of antibody candidates designed to go further
The Open Targets Blog
JULY 23, 2025
How can you work out the function of a particular gene or protein across different cell types and functions? If you perturb it—modify it and observe the consequences—you can start to unravel what its biological role might be, and determine whether the effects are unique to one cell type or whether they propagate across different cell contexts.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Covalent Modifiers
JULY 23, 2025
Fernando, M. C., Craven, G. B., & Shokat, K. M. Small GTPases, 2024 15(1), 1–7. [link] KRAS is the most frequently mutated oncogene in human cancer. In multiple types of cancer, a missense mutation at codon 12 substitutes a glycine for a cysteine, causing hyperactivation of the GTPase and enhanced MAPK signalling. Recent drug discovery efforts culminating from work during the past decade have resulted in two FDA-approved inhibitors, sotorasib and adagrasib, which target the KRASG12C mutant a
Science Daily: Pharmacology News
JULY 20, 2025
What scientists once dismissed as junk DNA may actually be some of the most powerful code in our genome. A new international study reveals that ancient viral DNA buried in our genes plays an active role in controlling how other genes are turned on or off, especially during early human development. These sequences, originally from long-extinct viruses, have evolved to act like tiny genetic switches.
Crown Bioscience
JULY 21, 2025
In the complex landscape of oncology research and drug development, reliable preclinical models are crucial. Among various available platforms, cell line-derived xenografts (CDX) stand out as a robust and highly valuable model system, offering unique advantages for understanding tumor biology, drug efficacy, and therapeutic potential. This article explores the pivotal role of CDX models in preclinical cancer research, emphasizing their utility in drug discovery and development processes.
Drug Target Review
JULY 21, 2025
In Part 2 of our conversation with Layla Hosseini-Gerami, Chief Data Science Officer at Ignota Labs , we explore the many forms of toxicity and how AI-powered tools like omics and cell painting are transforming early prediction in pre-clinical research. The conversation revealed important distinctions between different types of toxicity and our current ability to predict them: “For certain types of toxicity like liver and cardio, I think those are quite well understood in terms of the mech
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Broad Institute
JULY 18, 2025
Drug Discovery at the Broad Institute By Rose Circeo July 18, 2025 Breadcrumb Home Drug Discovery at the Broad Institute Broad Institute is home to a community of drug development experts who collaborate closely with other Broad scientists to turn discoveries about the biological roots of disease into new medicines. Broad researchers use innovative approaches to accelerate the development of new drugs, tackling projects that might be viewed as too risky or early-stage for a company to take on.
Chemical Biology and Drug Design
JULY 23, 2025
Liver cancer is a form of aggressive tumor, with HCC accounting for most of its occurrences. Traditional Chinese herbal medicines are well-known for their low risks of adverse events and anticancer effects. HMA, the main active ingredient of Hedyotis diffusa Willd , has been shown to suppress the growth of several malignancies. Therefore, this study examined the effects of HMA in HCC.
Science Daily: Pharmacology News
JULY 18, 2025
In a groundbreaking UK first, eight healthy babies have been born using an IVF technique that includes DNA from three people—two parents and a female donor. The process, known as pronuclear transfer, was designed to prevent the inheritance of devastating mitochondrial diseases passed down through the mother’s DNA. The early results are highly promising: all the babies are developing normally, and the disease-causing mutations are undetectable or present at levels too low to cause harm.
Sygnature Discovery
JULY 24, 2025
Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million investment. In today’s demanding drug discovery landscape, accelerating time to value inflection remains a top industry priority.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Target Review
JULY 19, 2025
Maria Knaub, Senior Medical Affairs Operations Lead at Terumo Blood and Cell Technologies (Terumo BCT), brings a unique blend of frontline experience and scientific expertise to the fore of cell therapy innovation. Her background as a paramedic and PhD in cancer biology have led Maria to lead global medical affairs efforts focused on advancing cell and gene therapies (CGTs).
thought leadership
JULY 20, 2025
Launching a clinical trial in Europe is a complex but rewarding endeavor, requiring careful navigation of regulatory frameworks, ethical requirements, and submission processes. Recent regulatory changes, including the transition from the EU Clinical Trial Directive to the EU Clinical Trial Regulation (EU CTR) , have harmonized approval pathways, enabling Sponsors to submit a single application covering both the applicable regulatory authorities and ethics committees through the Clinical Trial In
Chemical Biology and Drug Design
JULY 20, 2025
New thiadiazole-benzenesulfonamide hybrids having the pharmacophoric features of both B-Raf and VEGFR-2 inhibitors were designed and synthesized as potent anti-cancer agents. ABSTRACT A new group of thiadiazole-benzenesulfonamide hybrids was designed, synthesized, and biologically evaluated as potential dual inhibitors targeting B-Raf and VEGFR-2 for cancer therapy.
Science Daily: Pharmacology News
JULY 23, 2025
Scientists have discovered a sugar compound from deep-sea bacteria that can destroy cancer cells in a dramatic way. This natural substance, produced by microbes living in the ocean, causes cancer cells to undergo a fiery form of cell death, essentially making them self-destruct. In lab tests and in mice with liver cancer, the compound not only stopped tumors from growing, but also activated the immune system to fight back.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Fierce BioTech
JULY 18, 2025
Computer-Aided Drug Design and Workload Automation scox Fri, 07/18/2025 - 11:17 Tue, 08/26/2025 - 13:00 Resource Type Webinar Nikhil Venkat Computer-aided drug design (CADD) combining computational chemistry, molecular modeling, and rational drug design together with artificial intelligence (AI) and machine learning are rapidly changing the technological landscape of drug discovery.
Drug Target Review
JULY 18, 2025
Immuno-oncology has transformed cancer treatment, but for many patients, tumours remain resistant to even the most advanced immune checkpoint inhibitors. Domain Therapeutics is addressing this challenge by focusing on G protein-coupled receptors (GPCRs) – a well-validated and the largest family of drug targets that remains underexplored in cancer and inflammation.
BioPharma Drive: Drug Pricing
JULY 18, 2025
The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have become more difficult after the negative advisory committee vote.
Predictive Oncology
JULY 21, 2025
Drug repurposing using the Predictive Oncology machine learning approach and proprietary biobank of frozen dissociated tumor cells (DTCs) is outlined in this new white paper. An expedient workflow for identifying drugs that are good candidates for repurposing is demonstrated in this brand-new white paper. The Predictive Oncology machine learning approach paired with our proprietary biobank of frozen dissociated tumor cells (DTCs) offers a screening opportunity for many repurposing candidates to
PPD
JULY 18, 2025
Effective communication with regulatory authorities is critical for small biotech companies, as it is often the key to success in clinical trials. When small and emerging companies are able to build strong, trust-based relationships with regulators, they often see benefits like reduced development risk and accelerated timelines. However, to achieve these benefits, sponsors must have experience in and knowledge of the regulatory landscape.
Collaborative Drug
JULY 24, 2025
CDD Vault Update (July #2 2025) Search Inventory by Molecule & Batch Fields, Protocol Plate Locations, Stoichiometry Table Debiting, Synonym Links in ELN, Chemical Properties in Structure Editor
Drug Patent Watch
JULY 24, 2025
"Patent Strategy 2.0: Why Your Law Firm's Playbook May Be Holding You Back As the pharmaceutical industry continues to evolve at breakneck speed, one thing remains constant: the importance of a robust patent strategy. But are your lawyers playing by the same old rules? A new framework is emerging that's shaking up the status quo and giving companies a competitive edge.
ACTO
JULY 23, 2025
A Specialized Practice Environment to Sharpen Clinical Fluency, Master Product Messaging, and Drive Continuous Improvement Through a Gamified Experience BTORONTO and NEW YORK– July 24, 2025 — ACTO , a leader in AI-first commercial learning, enablement, and customer engagement solutions for life sciences and a Veeva Product Partner and member of the Veeva AI Partner Program, today announced the launch of CxZone , the first and only AI-simulated roleplay solution exclusively designed for pharmaceu
Science Daily: Pharmacology News
JULY 23, 2025
HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers successfully suppressed the virus in mice and discovered a way to kill infected cells, offering hope for the first preventative and curative treatments.
Alta Sciences
JULY 18, 2025
Highlights From the 2025 American Society for Mass Spectrometry Conference | By Jean-François Larocque and Benjamin Charron aasimakopoulos Tue, 07/22/2025 - 18:05 We were thrilled to represent Altasciences at this year’s American Society for Mass Spectrometry (ASMS) conference in Baltimore. With 6,000 scientists, students, and industry professionals from around the globe in attendance, it was an excellent opportunity to learn about the latest developments in mass spectrometry and share insights
Drugs.com
MAY 14, 2025
WEDNESDAY, May 14, 2025 -- Migraines don’t just cause headaches. These attacks often are accompanied by symptoms like light and sound sensitivity, nausea, neck pain and dizziness. What’s more, those non-headache symptoms tend to crop.
Expert insights. Personalized for you.
277 
Let's personalize your content